The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Treatment-Resistant Bipolar Depression: A STEP-BD Equipoise Randomized Effectiveness Trial of Antidepressant Augmentation With Lamotrigine, Inositol, or Risperidone
Abstract
OBJECTIVE: Clinicians have few evidence-based options for the management of treatment-resistant bipolar depression. This study represents the first randomized trial of competing options for treatment-resistant bipolar depression and assesses the effectiveness and safety of antidepressant augmentation with lamotrigine, inositol, and risperidone. METHOD: Participants (N=66) were patients with bipolar I or bipolar II disorder enrolled in the NIMH Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). All patients were in a current major depressive episode that was nonresponsive to a combination of adequate doses of established mood stabilizers plus at least one antidepressant. Patients were randomly assigned to open-label adjunctive treatment with lamotrigine, inositol, or risperidone for up to 16 weeks. The primary outcome measure was the rate of recovery, defined as no more than two symptoms meeting DSM-IV threshold criteria for a mood episode and no significant symptoms present for 8 weeks. RESULTS: No significant between-group differences were seen when any pair of treatments were compared on the primary outcome measure. However, the recovery rate with lamotrigine was 23.8%, whereas the recovery rates with inositol and risperidone were 17.4% and 4.6%, respectively. Patients receiving lamotrigine had lower depression ratings and Clinical Global Impression severity scores as well as greater Global Assessment of Functioning scores compared with those receiving inositol and risperidone. CONCLUSIONS: No differences were found in primary pairwise comparison analyses of open-label augmentation with lamotrigine, inositol, or risperidone. Post hoc secondary analyses suggest that lamotrigine may be superior to inositol and risperidone in improving treatment-resistant bipolar depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Judd, L. L., Akiskal, H. S., Schettler, P. J., Coryell, W., Endicott, J., Maser, J. D., Solomon, D. A., Leon, A. C., & Keller, M. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.3.261 · Cited by 1,243
Calabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E., Rudd, G. D., & The Lamictal 602 Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0203 · Cited by 1,054
Self-citationTohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908
Self-citationCalabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883
Self-citationBowden, C. L. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.4.392 · Cited by 658
Calabrese, J. R., Bowden, C. L., Sachs, G., Yatham, L. N., Behnke, K., Mehtonen, O.-P., Montgomery, P., Ascher, J., Paska, W., Earl, N., et al. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0906 · Cited by 635
Self-citation
Cited by
Goodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Self-citationDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
“Compared with our previous study with ketamine in patients with treatment-resistant major depressive disorder,(34) we found (1) more rapid onset of antidepressant effects (40 vs 110 minutes), (2) a higher response rate at 40 minutes (56% vs 11%) but lower at day 1 (42% vs 71%), (3) similar remission rates at day 1 (31…”
ResultTargeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
Magnetic Resonance Spectroscopy Studies of Glutamate-Related Abnormalities in Mood Disorders
Yüksel, C., & Öngür, D. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.016 · Cited by 493
Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., & Tomson, T. (2007) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.10.008 · Cited by 477
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & WFSBP Task Force On Treatment Guidelines For Bipolar Disorders (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903555881 · Cited by 399
“…Grade (RG) Critical references and comments Dose ranges or maximum dosages used in studies Inositol lithium or valproate D 5 (Evins et al. 2006; Nierenberg et al. 2006) Inositol: up to 22 g Omega 3 fatty acids lithium or valproate D 5 (Frangou et al. 2006; Keck et al. 2006) EPA: 1–8…”
BackgroundInfluentialJohannessen Landmark, C. (2008) · CNS Drugs · doi:10.2165/00023210-200822010-00003 · Cited by 316
Collaborative care for bipolar disorder, Part II: impact on clinical outcome, function, and costs.
Bauer, M. S., McBride, L., Williford, W. O., Glick, H., Kinosian, B., Altshuler, L., Beresford, T., Kilbourne, A. M., & Sajatovic, M. (2006) · Psychiatric Services · doi:10.1176/ps.2006.57.7.937 · Cited by 312
Self-citationNery, F. G., Monkul, E. S., Hatch, J. P., Fonseca, M., Zunta‐Soares, G. B., Frey, B. N., Bowden, C. L., & Soares, J. C. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.912 · Cited by 298
Yatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S. V., MacQueen, G., McIntyre, R. S., Sharma, V., Beaulieu, S., & for CANMAT guidelines group (2006) · Bipolar Disorders · doi:10.1111/j.1399-5618.2006.00432.x · Cited by 264
Bahji, A., Ermacora, D., Stephenson, C., Hawken, E. R., & Vazquez, G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.030 · Cited by 139
Bauer, M. S., McBride, L., Williford, W. O., Glick, H., Kinosian, B., Altshuler, L., Beresford, T., Kilbourne, A. M., & Sajatovic, M. (2006) · Psychiatric Services · doi:10.1176/ps.2006.57.7.927 · Cited by 138
“Underscoring the problems associated with undertreatment, the low medication response rates in recent real-world clinical trials for depression (18,19), schizophrenia (20), and bipolar disorder (21) indicate that more comprehensive approaches for such illnesses are warranted.”
BackgroundSelf-citationRisperidone for Treatment-Refractory Major Depressive Disorder: A Randomized Trial
Mahmoud, R. A., Pandina, G. J., Turkoz, I., Kosik-Gonzalez, C., Canuso, C. M., Kujawa, M. J., & Gharabawi-Garibaldi, G. M. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-9-200711060-00003 · Cited by 140
Ravindran, A. V., & da Silva, T. L. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.05.042 · Cited by 121
Novel glutamatergic agents for major depressive disorder and bipolar disorder
Machado-Vieira, R., Ibrahim, L., Henter, I. D., & Zarate, C. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.010 · Cited by 92
Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder
Fountoulakis, K. N., Vieta, E., Siamouli, M., Valenti, M., Magiria, S., Oral, T., Fresno, D., Giannakopoulos, P., & Kaprinis, G. S. (2007) · Annals of General Psychiatry · doi:10.1186/1744-859x-6-27 · Cited by 76
“for placebo [85,100-107].”
Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety
Sheehan, D. V., McElroy, S. L., Harnett-Sheehan, K., Keck, P. E., Janavs, J., Rogers, J., Gonzalez, R., Shivakumar, G., & Suppes, T. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.10.005 · Cited by 69
“The former would be supported by our findings that risperidone did not significantly reduce depressive symptoms compared with placebo along with the study by Nierenberg et al. (2006) showing that this antipsychotic may not be effective in acute bipolar depression.”
ResultNutrition and bipolar disorder: a systematic review
Gabriel, F. C., Oliveira, M., Martella, B. D. M., Berk, M., Brietzke, E., Jacka, F. N., & Lafer, B. (2023) · Nutritional Neuroscience · doi:10.1080/1028415x.2022.2077031 · Cited by 59
“…et al., 2020 low medium Low Low low no Mehrpooya et al., 2018 low medium Low Medium low yes Murphy et al., 2012 low high Low Medium low yes Nierenberg et al., 2006 low medium High High high no Nierenberg et al., 2017 n/a medium n/a Medium high no Osher et al., 2005 n/a high n/a Medium…”
BackgroundSajatovic, M., Gildengers, A., Al Jurdi, R. K., Gyulai, L., Cassidy, K. A., Greenberg, R. L., Bruce, M. L., Mulsant, B. H., Ten Have, T., & Young, R. C. (2011) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00923.x · Cited by 49
Kim, W. S. H., Dimick, M. K., Omrin, D., Mitchell, R. H. B., Riegert, D., Levitt, A., Schaffer, A., Belo, S., Iazzetta, J., Detzler, G., et al. (2023) · Bipolar Disorders · doi:10.1111/bdi.13288 · Cited by 24
Lamotrigine plus Quetiapine Combination Therapy in Treatment-Resistant Bipolar Depression
Ahn, Y. M., Nam, J. Y., Culver, J. L., Marsh, W. K., Bonner, J. C., & Ketter, T. A. (2011) · Annals of Clinical Psychiatry · doi:10.1177/104012371102300104 · Cited by 23
Self-citationA factor analytic study in bipolar depression, and response to lamotrigine
Mitchell, P. B., Hadzi-Pavlovic, D., Evoniuk, G., Calabrese, J. R., & Bowden, C. L. (2013) · CNS Spectrums · doi:10.1017/s1092852913000291 · Cited by 20
Self-citation
Metadata
- Authors
- Nierenberg, A. A., Ostacher, M. J., Calabrese, J. R., Ketter, T. A., Marangell, L. B., Miklowitz, D. J., Miyahara, S., Bauer, M. S., Thase, M. E., Wisniewski, S. R., Sachs, G. S., & STEP-BD Investigators
- Venue
- American Journal of Psychiatry
- Published
- 2006-02-01
- Volume
- 163
- Issue
- 2
- Pages
- 210-216
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2109545626
- Cited by
- 257
- References
- 37
- FWCI
- 17.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.